Masafumi Kurosumi Selected Research

Fluorouracil (Carac)

2/2021	Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial).
9/2015	ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
5/2013	Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
2/2012	Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
7/2011	Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
1/2005	Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masafumi Kurosumi Research Topics

Disease

91	Breast Neoplasms (Breast Cancer) 07/2022 - 01/2002
66	Neoplasms (Cancer) 02/2022 - 01/2003
15	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2007
5	Carcinoma (Carcinomatosis) 11/2012 - 01/2002
4	Triple Negative Breast Neoplasms 11/2019 - 03/2011
3	Disease Progression 06/2018 - 02/2014
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2017 - 12/2013
3	Carcinogenesis 07/2017 - 08/2009
3	Lymphatic Metastasis 07/2017 - 09/2015
3	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 06/2012 - 08/2009
3	Neutropenia 08/2008 - 01/2006
2	Noninfiltrating Intraductal Carcinoma (DCIS) 03/2021 - 12/2003
2	Hepatocellular Carcinoma (Hepatoma) 07/2017 - 05/2008
2	Colonic Neoplasms (Colon Cancer) 01/2016 - 05/2008
2	Stomach Neoplasms (Stomach Cancer) 11/2012 - 11/2011
2	Pathologic Complete Response 02/2012 - 01/2006
2	Intestinal Neoplasms (Intestinal Cancer) 11/2011 - 08/2009
2	Margins of Excision 03/2010 - 08/2009
2	Edema (Dropsy) 10/2007 - 01/2005
2	Febrile Neutropenia 10/2007 - 10/2006
2	Ductal Carcinoma 01/2007 - 07/2003
2	Leukopenia 10/2006 - 01/2006
1	Residual Neoplasm 01/2019
1	Alopecia (Baldness) 06/2018
1	Multiple Endocrine Neoplasia Type 1 11/2017
1	Neuroblastoma 07/2017

Drug/Important Bio-Agent (IBA)

23	Estrogen ReceptorsIBA 09/2021 - 06/2004
20	Hormones (Hormone)IBA 09/2021 - 01/2003
17	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2006
14	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 01/2006
12	ErbB Receptors (EGF Receptor)IBA 09/2021 - 12/2007
12	Docetaxel (Taxotere)FDA Link 09/2015 - 01/2005
10	Estrogens (Estrogen)FDA Link 03/2018 - 06/2004
9	human ERBB2 proteinIBA 01/2022 - 10/2008
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2021 - 01/2005
9	Proteins (Proteins, Gene)FDA Link 06/2019 - 01/2009
8	Epirubicin (Ellence)FDA LinkGeneric 09/2015 - 01/2005
6	Phenobarbital (Luminal)FDA Link 01/2022 - 12/2007
6	Fluorouracil (Carac)FDA LinkGeneric 02/2021 - 01/2005
6	Paclitaxel (Taxol)FDA LinkGeneric 06/2018 - 01/2007
6	Aromatase InhibitorsIBA 01/2018 - 06/2005
4	Messenger RNA (mRNA)IBA 02/2022 - 12/2012
4	Biomarkers (Surrogate Marker)IBA 10/2019 - 07/2010
4	AnthracyclinesIBA 01/2017 - 01/2010
4	taxaneIBA 01/2017 - 01/2006
4	Tamoxifen FDA LinkGeneric 04/2011 - 10/2007
3	exemestane (Aromasin)FDA Link 09/2021 - 01/2008
3	Biological ProductsIBA 03/2019 - 12/2007
3	Epidermal Growth Factor (EGF)IBA 07/2017 - 01/2006
3	Taxoids (Taxanes)IBA 09/2015 - 01/2006
3	Insulin (Novolin)FDA Link 08/2014 - 11/2011
3	Green Fluorescent ProteinsIBA 01/2014 - 06/2005
3	AndrogensIBA 01/2014 - 11/2006
3	SteroidsIBA 01/2014 - 01/2003
3	Formaldehyde (Formol)FDA Link 11/2013 - 10/2008
3	Keratin-5 (Keratin 5)IBA 03/2011 - 12/2007
3	Tumor Biomarkers (Tumor Markers)IBA 05/2008 - 01/2003
2	antineoplaston A10 (A 10)IBA 09/2021 - 08/2010
2	UracilIBA 02/2021 - 10/2007
2	TegafurIBA 02/2021 - 10/2007
2	Bevacizumab (Avastin)FDA Link 06/2018 - 01/2017
2	eribulin FDA Link 06/2018 - 01/2016
2	Indicators and Reagents (Reagents)IBA 01/2018 - 01/2017
2	LigandsIBA 12/2017 - 08/2009
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 06/2008
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2016 - 08/2009
2	Aromatase (CYP19)IBA 01/2014 - 06/2005
2	Testosterone (Sustanon)FDA Link 06/2013 - 06/2005
2	ParaffinIBA 10/2010 - 10/2008
2	Keratins (Keratin)IBA 06/2009 - 01/2007
2	EnzymesIBA 10/2007 - 06/2005
2	Coloring Agents (Dyes)IBA 01/2006 - 01/2006
2	thiamine triphosphorate (TTP)IBA 01/2006 - 01/2003
2	Thymidine PhosphorylaseIBA 08/2004 - 01/2002
1	RNA (Ribonucleic Acid)IBA 02/2022
1	Large Neutral Amino Acid-Transporter 1IBA 01/2022
1	Amino Acid Transport Systems (Amino Acid Transporter)IBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 03/2021
1	Methotrexate (Mexate)FDA LinkGeneric 02/2021
1	B7-H1 AntigenIBA 11/2019
1	Cyclin D1IBA 01/2019
1	Fulvestrant (Faslodex)FDA Link 01/2019
1	Progesterone FDA LinkGeneric 03/2018
1	Letrozole (Femara)FDA LinkGeneric 01/2018
1	Immune Checkpoint InhibitorsIBA 12/2017
1	activin AIBA 07/2017

Therapy/Procedure

48	Therapeutics 01/2022 - 01/2002
17	Neoadjuvant Therapy 01/2019 - 01/2005
14	Drug Therapy (Chemotherapy) 12/2017 - 01/2005
6	Radiotherapy 07/2017 - 09/2006
6	Mastectomy (Mammectomy) 05/2015 - 01/2007
5	Adjuvant Chemotherapy 07/2022 - 07/2003
5	Segmental Mastectomy (Lumpectomy) 06/2013 - 01/2005
4	Lymph Node Excision (Lymph Node Dissection) 01/2010 - 01/2007
3	Gastrectomy 11/2017 - 11/2011
3	Colectomy 11/2012 - 11/2010
2	Pancreatectomy 11/2012 - 11/2011
2	Molecular Targeted Therapy 11/2012 - 01/2009
1	Duration of Therapy 09/2021
1	Lasers (Laser) 06/2019